Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Current Deferred Revenue (2023 - 2026)

BioScience Health Innovations has reported Current Deferred Revenue over the past 4 years, most recently at $76749.0 for Q1 2026.

  • Quarterly Current Deferred Revenue rose 53.38% to $76749.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $76749.0 through Mar 2026, up 53.38% year-over-year, with the annual reading at $136590.0 for FY2025, 461.43% up from the prior year.
  • Current Deferred Revenue was $76749.0 for Q1 2026 at BioScience Health Innovations, down from $136590.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $248659.0 in Q2 2025 and troughed at $3949.0 in Q4 2023.
  • The 4-year median for Current Deferred Revenue is $76749.0 (2026), against an average of $93043.6.
  • Year-over-year, Current Deferred Revenue skyrocketed 516.08% in 2024 and then soared 53.38% in 2026.
  • A 4-year view of Current Deferred Revenue shows it stood at $3949.0 in 2023, then skyrocketed by 516.08% to $24329.0 in 2024, then surged by 461.43% to $136590.0 in 2025, then tumbled by 43.81% to $76749.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Current Deferred Revenue are $76749.0 (Q1 2026), $136590.0 (Q4 2025), and $110991.0 (Q3 2025).